These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33813274)

  • 1. Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation.
    Padhi AK; Tripathi T
    Biochem Biophys Res Commun; 2021 May; 555():147-153. PubMed ID: 33813274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.
    Duan Y; Zhou H; Liu X; Iketani S; Lin M; Zhang X; Bian Q; Wang H; Sun H; Hong SJ; Culbertson B; Mohri H; Luck MI; Zhu Y; Liu X; Lu Y; Yang X; Yang K; Sabo Y; Chavez A; Goff SP; Rao Z; Ho DD; Yang H
    Nature; 2023 Oct; 622(7982):376-382. PubMed ID: 37696289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
    Yuda GPWC; Hanif N; Hermawan A
    Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control.
    Salpini R; Alkhatib M; Costa G; Piermatteo L; Ambrosio FA; Di Maio VC; Scutari R; Duca L; Berno G; Fabeni L; Alcaro S; Ceccherini-Silberstein F; Artese A; Svicher V
    J Antimicrob Chemother; 2021 Jan; 76(2):396-412. PubMed ID: 33254234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
    Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
    Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
    Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
    J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations.
    Liang S; Liu X; Zhang S; Li M; Zhang Q; Chen J
    Phys Chem Chem Phys; 2022 Jan; 24(3):1743-1759. PubMed ID: 34985081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
    Welsch C; Shimakami T; Hartmann C; Yang Y; Domingues FS; Lengauer T; Zeuzem S; Lemon SM
    Gastroenterology; 2012 Mar; 142(3):654-63. PubMed ID: 22155364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.
    Padhi AK; Tripathi T
    Biochem Biophys Res Commun; 2022 Nov; 629():54-60. PubMed ID: 36113178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.
    Kumar R; Kumar V; Lee KW
    Comput Biol Med; 2021 Mar; 130():104186. PubMed ID: 33360831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
    Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
    J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
    Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
    Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
    Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
    Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
    Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.
    Zhang S; Krumberger M; Morris MA; Parrocha CMT; Kreutzer AG; Nowick JS
    Eur J Med Chem; 2021 Jun; 218():113390. PubMed ID: 33812315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.